1
|
Morales BGDV, Evaristo JAM, Oliveira GARDE, Garay AFG, Diaz JJAR, Arruda A, Pereira SS, Zanchi FB. Expression and purification of active shikimate dehydrogenase from Plasmodium falciparum. AN ACAD BRAS CIENC 2024; 96:e20230382. [PMID: 38422345 DOI: 10.1590/0001-3765202420230382] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2023] [Accepted: 10/02/2023] [Indexed: 03/02/2024] Open
Abstract
Plasmodium falciparum is known to cause severe malaria, current treatment consists in artemisinin-based combination therapy, but resistance can lead to treatment failure. Knowledge concerning P. falciparum essential proteins can be used for searching new antimalarials, among these a potential candidate is shikimate dehydrogenase (SDH), an enzyme part of the shikimate pathway which is responsible for producing endogenous aromatic amino acids. SDH from P. falciparum (PfSDH) is unexplored by the scientific community, therefore, this study aims to establish the first protocol for active PfSDH expression. Putative PfSDH nucleotide sequence was used to construct an optimized expression vector pET28a+PfSDH inserted in E. coli BL21(DE3). As a result, optimal expression conditions were acquired by varying IPTG and temperature through time. Western Blot analysis was applied to verify appropriate PfSDH expression, solubilization and purification started with lysis followed by two-steps IMAC purification. Enzyme activity was measured spectrophotometrically by NADPH oxidation, optimal PfSDH expression occur at 0.1 mM IPTG for 48 hours growing at 37 °C and shaking at 200 rpm, recombinant PfSDH obtained after purification was soluble, pure and its physiological catalysis was confirmed. Thus, this study describes the first protocol for heterologous expression of PfSDH in soluble and active form.
Collapse
Affiliation(s)
- Bruno G Dalla Vecchia Morales
- Oswaldo Cruz Foundation Rondônia (FIOCRUZ/RO), Laboratory of Bioinformatics and Medicinal Chemistry, BR 364, km 9,5, Centro, 76801-059 Porto Velho, RO, Brazil
- Federal University of Rondonia (UNIR), BR 364, km 9,5, Centro, 76801-059 Porto Velho, RO, Brazil
- São Lucas University Center (UniSL), Alexandre Guimarães Street, 1927, Areal, 76804-373 Porto Velho, RO, Brazil
| | - Joseph Albert M Evaristo
- Oswaldo Cruz Foundation Rondônia (FIOCRUZ/RO), Laboratory of Bioinformatics and Medicinal Chemistry, BR 364, km 9,5, Centro, 76801-059 Porto Velho, RO, Brazil
| | - George A R DE Oliveira
- Oswaldo Cruz Foundation Rondônia (FIOCRUZ/RO), Laboratory of Bioinformatics and Medicinal Chemistry, BR 364, km 9,5, Centro, 76801-059 Porto Velho, RO, Brazil
- Oswaldo Cruz Institute (IOC), Brasil Avenue 4365, Manguinhos, 21040-900 Rio de Janeiro, RJ, Brazil
| | - Ana Fidelina G Garay
- Centro para el Desarrollo de la Investigación Científica (CEDIC), P975+F58, Manduvira, Asuncion, Paraguay
| | - Jorge Javier A R Diaz
- Centro para el Desarrollo de la Investigación Científica (CEDIC), P975+F58, Manduvira, Asuncion, Paraguay
| | - Andrelisse Arruda
- Oswaldo Cruz Foundation Rondônia (FIOCRUZ/RO), Laboratory of Antibodies Engineering, Beira Street, 7671, Lagoa, 76812-245 Porto Velho, RO, Brazil
- Oswaldo Cruz Foundation Brasília (FIOCRUZ BRASÍLIA), L3 North Avenue, Gleba A, 70904-130 Brasília, DF, Brazil
| | - Soraya S Pereira
- Federal University of Rondonia (UNIR), BR 364, km 9,5, Centro, 76801-059 Porto Velho, RO, Brazil
- Oswaldo Cruz Foundation Rondônia (FIOCRUZ/RO), Laboratory of Antibodies Engineering, Beira Street, 7671, Lagoa, 76812-245 Porto Velho, RO, Brazil
| | - Fernando B Zanchi
- Oswaldo Cruz Foundation Rondônia (FIOCRUZ/RO), Laboratory of Bioinformatics and Medicinal Chemistry, BR 364, km 9,5, Centro, 76801-059 Porto Velho, RO, Brazil
- Federal University of Rondonia (UNIR), BR 364, km 9,5, Centro, 76801-059 Porto Velho, RO, Brazil
- Oswaldo Cruz Institute (IOC), Brasil Avenue 4365, Manguinhos, 21040-900 Rio de Janeiro, RJ, Brazil
| |
Collapse
|
2
|
Fernández-Soto P, Casulli J, Solano-Castro D, Rodríguez-Fernández P, Jowitt TA, Travis MA, Cavet JS, Tabernero L. Discovery of uncompetitive inhibitors of SapM that compromise intracellular survival of Mycobacterium tuberculosis. Sci Rep 2021; 11:7667. [PMID: 33828158 PMCID: PMC8027839 DOI: 10.1038/s41598-021-87117-x] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2020] [Accepted: 02/15/2021] [Indexed: 12/28/2022] Open
Abstract
SapM is a secreted virulence factor from Mycobacterium tuberculosis critical for pathogen survival and persistence inside the host. Its full potential as a target for tuberculosis treatment has not yet been exploited because of the lack of potent inhibitors available. By screening over 1500 small molecules, we have identified new potent and selective inhibitors of SapM with an uncompetitive mechanism of inhibition. The best inhibitors share a trihydroxy-benzene moiety essential for activity. Importantly, the inhibitors significantly reduce mycobacterial burden in infected human macrophages at 1 µM, and they are selective with respect to other mycobacterial and human phosphatases. The best inhibitor also reduces intracellular burden of Francisella tularensis, which secretes the virulence factor AcpA, a homologue of SapM, with the same mechanism of catalysis and inhibition. Our findings demonstrate that inhibition of SapM with small molecule inhibitors is efficient in reducing intracellular mycobacterial survival in host macrophages and confirm SapM as a potential therapeutic target. These initial compounds have favourable physico-chemical properties and provide a basis for exploration towards the development of new tuberculosis treatments. The efficacy of a SapM inhibitor in reducing Francisella tularensis intracellular burden suggests the potential for developing broad-spectrum antivirulence agents to treat microbial infections.
Collapse
Affiliation(s)
- Paulina Fernández-Soto
- School of Biological Sciences, Faculty of Biology Medicine and Health, Manchester Academic Health Science Centre, University of Manchester, Manchester, M13 9PT, UK
| | - Joshua Casulli
- School of Biological Sciences, Faculty of Biology Medicine and Health, Manchester Academic Health Science Centre, University of Manchester, Manchester, M13 9PT, UK.,Lydia Becker Institute for Immunology and Inflammation, University of Manchester, Manchester, UK.,Wellcome Centre for Cell-Matrix Research, University of Manchester, Manchester, UK
| | - Danilo Solano-Castro
- School of Biological Sciences, Faculty of Biology Medicine and Health, Manchester Academic Health Science Centre, University of Manchester, Manchester, M13 9PT, UK
| | - Pablo Rodríguez-Fernández
- School of Biological Sciences, Faculty of Biology Medicine and Health, Manchester Academic Health Science Centre, University of Manchester, Manchester, M13 9PT, UK
| | - Thomas A Jowitt
- School of Biological Sciences, Faculty of Biology Medicine and Health, Manchester Academic Health Science Centre, University of Manchester, Manchester, M13 9PT, UK.,Wellcome Centre for Cell-Matrix Research, University of Manchester, Manchester, UK
| | - Mark A Travis
- School of Biological Sciences, Faculty of Biology Medicine and Health, Manchester Academic Health Science Centre, University of Manchester, Manchester, M13 9PT, UK.,Lydia Becker Institute for Immunology and Inflammation, University of Manchester, Manchester, UK.,Wellcome Centre for Cell-Matrix Research, University of Manchester, Manchester, UK
| | - Jennifer S Cavet
- School of Biological Sciences, Faculty of Biology Medicine and Health, Manchester Academic Health Science Centre, University of Manchester, Manchester, M13 9PT, UK
| | - Lydia Tabernero
- School of Biological Sciences, Faculty of Biology Medicine and Health, Manchester Academic Health Science Centre, University of Manchester, Manchester, M13 9PT, UK. .,Lydia Becker Institute for Immunology and Inflammation, University of Manchester, Manchester, UK.
| |
Collapse
|
3
|
Rankine-Wilson LI, Shapira T, Sao Emani C, Av-Gay Y. From infection niche to therapeutic target: the intracellular lifestyle of Mycobacterium tuberculosis. MICROBIOLOGY (READING, ENGLAND) 2021; 167:001041. [PMID: 33826491 PMCID: PMC8289223 DOI: 10.1099/mic.0.001041] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/02/2020] [Accepted: 02/15/2021] [Indexed: 12/16/2022]
Abstract
Mycobacterium tuberculosis (Mtb) is an obligate human pathogen killing millions of people annually. Treatment for tuberculosis is lengthy and complicated, involving multiple drugs and often resulting in serious side effects and non-compliance. Mtb has developed numerous complex mechanisms enabling it to not only survive but replicate inside professional phagocytes. These mechanisms include, among others, overcoming the phagosome maturation process, inhibiting the acidification of the phagosome and inhibiting apoptosis. Within the past decade, technologies have been developed that enable a more accurate understanding of Mtb physiology within its intracellular niche, paving the way for more clinically relevant drug-development programmes. Here we review the molecular biology of Mtb pathogenesis offering a unique perspective on the use and development of therapies that target Mtb during its intracellular life stage.
Collapse
Affiliation(s)
| | - Tirosh Shapira
- Division of Infectious Disease, Department of Medicine, The University of British Columbia, Vancouver, Canada
| | - Carine Sao Emani
- Division of Infectious Disease, Department of Medicine, The University of British Columbia, Vancouver, Canada
| | - Yossef Av-Gay
- Department of Microbiology & Immunology, The University of British Columbia, Vancouver, Canada
- Division of Infectious Disease, Department of Medicine, The University of British Columbia, Vancouver, Canada
| |
Collapse
|